NGENF Nervgen Consolidation continues Possible entry ahead

OTC:NGENF   NervGen Pharma Corp
Nice long ~2 year consolidation is in progress, recent reject from the top side of wedge will present entry opportunities

Entry target ~ 1.15-1.35 (1.25 average)

Interesting medical treatments currently in trials

Long term play


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.